Reframing Global Biotech Innovation: Dialogue with RA Capital Management on Venture Building and Cross-Border Acceleration
2026-05-08On April 27, RA Capital Management, Biosparc, and True Light co-hosted the event “Dialogue with RA Capital: Innovation Paradigms & Cross-Border Acceleration” in Suzhou Industrial Park, China. The event brought together leading voices from global biotech and investment communities for an in-depth exchange on venture creation, BD strategies, and cross-border
Cross-Border Acceleration: Reshaping Innovation in a Global Context
During the keynote session, three speakers from RA Capital shared perspectives across three critical dimensions—empowerment, venture creation, and execution—offering a structured lens on the evolving biotech landscape.
Tess Cameron , Managing Director at RA Capital, highlighted the firm’s role within the global biotech ecosystem. Rather than positioning itself as a traditional capital provider, RA Capital actively aligns resources and capabilities with companies at different stages of development—supporting everything from early-stage decision-making to milestone execution.
Instead of following financing cycles, RA Capital focuses on a core question: What does the company need most at this stage?
She noted that cross-border collaboration is no longer optional—it is becoming a core capability. Within this shift, China is evolving from an “important market” into a critical node in the global innovation network, driven by its strengths in clinical translation and industrial coordination. Reflecting this view, RA Capital has accelerated its engagement in China over the past year, including increased on-the-ground presence, local team development, and direct investment exploration.
Rajeev Shah , Managing Partner at RA Capital, shared insights from over two decades of venture building and investment practice. He emphasized that drug development is inherently high-risk, capital-intensive, and characterized by long development timelines. He shared RA Capital’s philosophy through case studies, explaining how the firm identifyies a company’s fundamental value and provides the strategic resources needed to reach major clinical inflection points. This approach focuses on driving long-term growth for premium exits, rather than settling for premature transactions or short-term gains.
At the same time, he encouraged early and continuous engagement with the market, including proactive interaction with potential MNC partners. By combining R&D progression with ongoing market signaling, companies build market visibility and shape competitive positioning, and ultimately unlock stronger partnership or exit outcomes.
On M&A and partnerships, he reiterated a key principle:
“Companies are bought, not sold.”
Companies should be built as independent entities, with clear value anchors established through data generation and strategic interactions. Transactions are not endpoints, but integral moments in value realization.
Based on his experience leading multiple BD and M&A deals, Raj also shared a grounded view on the “myths and truths” of transactions: outcomes are determined not by negotiation alone, but by how consistently value is built and communicated over time.
Laura Shawver , Venture Partner at Raven, RA Capital’s healthcare incubator, and former President & CEO of Capstan Therapeutics, provided a founder-operator perspective on translating frontier science into investable assets. This marked her first in-depth sharing in China on the development journey of Capstan.
Focusing on in vivo CAR-T, a technically complex and high-barrier field, she emphasized the importance of maintaining deep focus on core programs and advancing them through data-driven milestones. Generating decision-enabling data is critical to reducing uncertainty and moving assets toward the clinic.
She also highlighted the importance of strategically designed clinical pathways—not only to validate science, but to provide clarity and confidence for potential partners. Early and continuous engagement with MNCs is essential, allowing companies to build market awareness and catalyze potential transactions over time.
As technologies become more complex, companies must think earlier about pathway design and execution strategy—including trade-offs, timing, and how to maintain leverage in interactions with industry partners.
Innovation Paradigms: From Single Assets to System Capabilities
The panel discussion, titled “Decoding Global Biotech Innovation Through In Vivo CAR-T and Cross-Border Collaboration,” shifted the conversation toward a central question: What defines a winning biotech company today?
Moderated by Yvonne Koh of ClavystBio, the panel brought together ex-Capstan team members Laura Shawver , former Capstan Chief Business Officer and current Raven Venture Partner Miguel Arcinas former Capstan Chief Medical Officer and current Raven Venture Partner Ramin Farzaneh-Far , and Hao Jia from True Light.
A shared view emerged: the competitive logic in biotech is evolving. It is no longer sufficient to ask whether a technology works. The more critical question is whether it can be translated into a clear, verifiable, fundable, and partnerable development pathway.
Key determinants of success now include:
Team-level decision-making quality
Early-stage clinical pathway design
Alignment between capital strategy and development milestones
In discussing platform companies, panelists noted that platforms do not inherently create value. For early-stage companies, the challenge lies in identifying a lead asset that can enter the clinic and be validated. This is especially critical in emerging areas like in vivo CAR-T, where differentiation must be clearly defined and supported by testable clinical hypotheses.
During the Q&A, this perspective was further reinforced. When asked about potential overcrowding in the in vivo CAR-T space, panelists reframed the issue:
success is not determined by timing, but by the ability to validate differentiation.
On cross-border collaboration, the discussion converged on a key insight: different regions offer distinct strengths, and the focus should not be on resource aggregation, but on pathway optimization. In this context, China is increasingly positioned as an integral node within global innovation pathways.
Connection as Infrastructure: The Long-Term Value of Global Ecosystems
A clear theme emerged throughout the discussion: biotech competition is shifting from isolated capabilities to the efficiency of connections across systems.
As an international life sciences innovation platform, Biosparc is positioning itself to build this connective infrastructure—linking global research institutions, industry resources, and capital networks. Through such integration, cross-border collaboration evolves from opportunistic interaction into a sustainable structural capability.
The collaboration with RA Capital, True Light, and a diverse group of ecosystem partners further reinforces this direction: value is amplified through coordination—and over time, such coordination becomes a sustainable / long-term competitive advantage.
Against the backdrop of continuous global innovation, the ability to connect and collaborate at scale is increasingly becoming a defining factor in the next phase of biotech innovation.